Targeting GPNMB reverses immune checkpoint inhibitors resistance in mouse models, suggesting that GPNMB can serve as both a prognostic marker for a potential therapeutic target in RCC patients (Chung et al., 2025). The gene discussed is GPNMB; the disease is renal cell carcinoma.